Development of thrombocytopenia during first-line treatment and survival outcomes in newly diagnosed multiple myeloma

Patrick W. Mellors; Moritz Binder; Francis K. Buadi; Martha Q. Lacy; Morie A. Gertz; Angela Dispenzieri; Suzanne R. Hayman; Prashant Kapoor; Wilson I. Gonsalves; Yi L. Hwa; Amie Fonder; Miriam Hobbs; Taxiarchis Kourelis; Rahma Warsame; Steven R. Zeldenrust; John A. Lust; Nelson Leung; Ronald S. Go; Robert A. Kyle; S. Vincent Rajkumar; Shaji K. Kumar

doi:10.1080/10428194.2019.1613536

Development of thrombocytopenia during first-line treatment and survival outcomes in newly diagnosed multiple myeloma

Patrick W. Mellors, Moritz Binder, Francis K. Buadi, Martha Q. Lacy, Morie A. Gertz, Angela Dispenzieri, Suzanne R. Hayman, Prashant Kapoor, Wilson I. Gonsalves, Yi L. Hwa, Amie Fonder, Miriam Hobbs, Taxiarchis Kourelis, Rahma Warsame, Steven R. Zeldenrust, John A. Lust, Nelson Leung, Ronald S. Go, Robert A. Kyle, S. Vincent RajkumarShaji K. Kumar

Hematology

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

The prognostic significance of novel agent-induced thrombocytopenia in newly diagnosed multiple myeloma (MM) is unknown. We identified 665 newly diagnosed patients receiving proteasome inhibitors and/or immunomodulators with pretreatment platelet counts ≥100,000/µL. Median progression-free survival (PFS) was 1.88 years (95% CI 1.48–2.38) for patients who developed treatment-related thrombocytopenia (<100,000/µL) within sixty days of initiation of first-line therapy, compared to 2.64 years (95% CI 2.39–2.78) in patients who did not (p =.042), while median overall survival (OS) was 5.70 years (95% CI 3.02–9.00) and 8.43 years (95% CI 6.62–9.17), respectively (p =.030). Platelet count reduction >70% from pretreatment baseline was similarly predictive of inferior PFS and OS. This is the first study to demonstrate the predictive and prognostic value of treatment-related thrombocytopenia in newly diagnosed MM.

Original language	English (US)
Pages (from-to)	2960-2967
Number of pages	8
Journal	Leukemia and Lymphoma
Volume	60
Issue number	12
DOIs	https://doi.org/10.1080/10428194.2019.1613536
State	Published - Oct 15 2019

Keywords

Multiple myeloma
prognosis
response
survival
thrombocytopenia

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1080/10428194.2019.1613536

Cite this

Mellors, P. W., Binder, M., Buadi, F. K., Lacy, M. Q., Gertz, M. A., Dispenzieri, A., Hayman, S. R., Kapoor, P., Gonsalves, W. I., Hwa, Y. L., Fonder, A., Hobbs, M., Kourelis, T., Warsame, R., Zeldenrust, S. R., Lust, J. A., Leung, N., Go, R. S., Kyle, R. A., ... Kumar, S. K. (2019). Development of thrombocytopenia during first-line treatment and survival outcomes in newly diagnosed multiple myeloma. Leukemia and Lymphoma, 60(12), 2960-2967. https://doi.org/10.1080/10428194.2019.1613536

Mellors, PW, Binder, M, Buadi, FK, Lacy, MQ , Gertz, MA , Dispenzieri, A, Hayman, SR, Kapoor, P , Gonsalves, WI, Hwa, YL, Fonder, A, Hobbs, M, Kourelis, T, Warsame, R, Zeldenrust, SR, Lust, JA, Leung, N, Go, RS, Kyle, RA, Rajkumar, SV & Kumar, SK 2019, 'Development of thrombocytopenia during first-line treatment and survival outcomes in newly diagnosed multiple myeloma', Leukemia and Lymphoma, vol. 60, no. 12, pp. 2960-2967. https://doi.org/10.1080/10428194.2019.1613536

@article{9bfc7075feac48cbb1a39ddba5cc6b06,

title = "Development of thrombocytopenia during first-line treatment and survival outcomes in newly diagnosed multiple myeloma",

abstract = "The prognostic significance of novel agent-induced thrombocytopenia in newly diagnosed multiple myeloma (MM) is unknown. We identified 665 newly diagnosed patients receiving proteasome inhibitors and/or immunomodulators with pretreatment platelet counts ≥100,000/µL. Median progression-free survival (PFS) was 1.88 years (95% CI 1.48–2.38) for patients who developed treatment-related thrombocytopenia (<100,000/µL) within sixty days of initiation of first-line therapy, compared to 2.64 years (95% CI 2.39–2.78) in patients who did not (p =.042), while median overall survival (OS) was 5.70 years (95% CI 3.02–9.00) and 8.43 years (95% CI 6.62–9.17), respectively (p =.030). Platelet count reduction >70% from pretreatment baseline was similarly predictive of inferior PFS and OS. This is the first study to demonstrate the predictive and prognostic value of treatment-related thrombocytopenia in newly diagnosed MM.",

keywords = "Multiple myeloma, prognosis, response, survival, thrombocytopenia",

author = "Mellors, {Patrick W.} and Moritz Binder and Buadi, {Francis K.} and Lacy, {Martha Q.} and Gertz, {Morie A.} and Angela Dispenzieri and Hayman, {Suzanne R.} and Prashant Kapoor and Gonsalves, {Wilson I.} and Hwa, {Yi L.} and Amie Fonder and Miriam Hobbs and Taxiarchis Kourelis and Rahma Warsame and Zeldenrust, {Steven R.} and Lust, {John A.} and Nelson Leung and Go, {Ronald S.} and Kyle, {Robert A.} and Rajkumar, {S. Vincent} and Kumar, {Shaji K.}",

note = "Publisher Copyright: {\textcopyright} 2019, {\textcopyright} 2019 Informa UK Limited, trading as Taylor & Francis Group.",

year = "2019",

month = oct,

day = "15",

doi = "10.1080/10428194.2019.1613536",

language = "English (US)",

volume = "60",

pages = "2960--2967",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Informa Healthcare",

number = "12",

}

TY - JOUR

T1 - Development of thrombocytopenia during first-line treatment and survival outcomes in newly diagnosed multiple myeloma

AU - Mellors, Patrick W.

AU - Binder, Moritz

AU - Buadi, Francis K.

AU - Lacy, Martha Q.

AU - Gertz, Morie A.

AU - Dispenzieri, Angela

AU - Hayman, Suzanne R.

AU - Kapoor, Prashant

AU - Gonsalves, Wilson I.

AU - Hwa, Yi L.

AU - Fonder, Amie

AU - Hobbs, Miriam

AU - Kourelis, Taxiarchis

AU - Warsame, Rahma

AU - Zeldenrust, Steven R.

AU - Lust, John A.

AU - Leung, Nelson

AU - Go, Ronald S.

AU - Kyle, Robert A.

AU - Rajkumar, S. Vincent

AU - Kumar, Shaji K.

PY - 2019/10/15

Y1 - 2019/10/15

N2 - The prognostic significance of novel agent-induced thrombocytopenia in newly diagnosed multiple myeloma (MM) is unknown. We identified 665 newly diagnosed patients receiving proteasome inhibitors and/or immunomodulators with pretreatment platelet counts ≥100,000/µL. Median progression-free survival (PFS) was 1.88 years (95% CI 1.48–2.38) for patients who developed treatment-related thrombocytopenia (<100,000/µL) within sixty days of initiation of first-line therapy, compared to 2.64 years (95% CI 2.39–2.78) in patients who did not (p =.042), while median overall survival (OS) was 5.70 years (95% CI 3.02–9.00) and 8.43 years (95% CI 6.62–9.17), respectively (p =.030). Platelet count reduction >70% from pretreatment baseline was similarly predictive of inferior PFS and OS. This is the first study to demonstrate the predictive and prognostic value of treatment-related thrombocytopenia in newly diagnosed MM.

AB - The prognostic significance of novel agent-induced thrombocytopenia in newly diagnosed multiple myeloma (MM) is unknown. We identified 665 newly diagnosed patients receiving proteasome inhibitors and/or immunomodulators with pretreatment platelet counts ≥100,000/µL. Median progression-free survival (PFS) was 1.88 years (95% CI 1.48–2.38) for patients who developed treatment-related thrombocytopenia (<100,000/µL) within sixty days of initiation of first-line therapy, compared to 2.64 years (95% CI 2.39–2.78) in patients who did not (p =.042), while median overall survival (OS) was 5.70 years (95% CI 3.02–9.00) and 8.43 years (95% CI 6.62–9.17), respectively (p =.030). Platelet count reduction >70% from pretreatment baseline was similarly predictive of inferior PFS and OS. This is the first study to demonstrate the predictive and prognostic value of treatment-related thrombocytopenia in newly diagnosed MM.

KW - Multiple myeloma

KW - prognosis

KW - response

KW - survival

KW - thrombocytopenia

UR - http://www.scopus.com/inward/record.url?scp=85066094519&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066094519&partnerID=8YFLogxK

U2 - 10.1080/10428194.2019.1613536

DO - 10.1080/10428194.2019.1613536

M3 - Article

C2 - 31096812

AN - SCOPUS:85066094519

SN - 1042-8194

VL - 60

SP - 2960

EP - 2967

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 12

ER -

Development of thrombocytopenia during first-line treatment and survival outcomes in newly diagnosed multiple myeloma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this